Peripheral Arterial Disease affects 8-12 million Americans. Further, some 21% of PAD patients will suffer a heart attack or stroke, face hospitalization, or die within one year. Yet 75% of people with PAD remain un-detected. Under-diagnosis results from the relative complexity and inaccessibility of testing equipment. FloChecTM was developed to provide clinicians an in-office tool to assess the risk of PAD in an objective manner. FloChec has been compared favorably to Doppler ABI in several studies and has received acceptance by hundreds of physicians use it their primary means of assessing patients at risk for PAD. Semler Scientific was founded by Herbert Semler, MD, FACC, an interventional cardiologist, to provide clinicians tools to detect PAD, and help them save limbs and lives.